AlloSure Heart is Now Validated and Commercially Available for Pediatric Heart Transplant Patients Under 15 AlloSure Kidney is Now Validated and Commercially Available for Simultaneous Pancreas-Kidney Transplant Patients CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. Both indications are appro

Full Year 2024 Revenue Grew 19% to $334 Million Expects Full Year 2025 Revenue of $365 Million to $375 Million CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenue of $86.6 million, increased 32% year-over-year Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, increased 14% year-over-year GAAP net income of $87.7 million, non-GAAP net income of $10.7 million, and positive adjusted EBITDA of $9.8 million, a significant improvement from the fourth quarter 2023 Cash flow from operations of

All Patent Claims Asserted Against CareDx are Found to Be Invalid CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor. The District Court ruled that the patents asserted against CareDx are invalid. The Court reached this determination because the patents failed to describe the claimed invention in sufficient detail. CareDx believes that the Court's decision brings this lawsuit to its rightful legal outcome and is

Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

4 - CareDx, Inc. (0001217234) (Issuer)

4 - CareDx, Inc. (0001217234) (Issuer)

4 - CareDx, Inc. (0001217234) (Issuer)

8-K - CareDx, Inc. (0001217234) (Filer)

8-K - CareDx, Inc. (0001217234) (Filer)

SCHEDULE 13G/A - CareDx, Inc. (0001217234) (Subject)

CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to a live webcast, pl

SC 13G/A - CareDx, Inc. (0001217234) (Subject)

SC 13G/A - CareDx, Inc. (0001217234) (Subject)

SC 13G/A - CareDx, Inc. (0001217234) (Subject)